Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces updates to its credit agreement and...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
Q2 2022 revenue of $15.5 million, Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million. Total Vascepa prescriptions grew 88% year-over-year, reflecting sequential growth of...
Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-label Public reimbursement for...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results on Thursday, August 11, 2022. The Company will hold a conference call...
Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label Public reimbursement for Vascepa is now...
New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will reimburse Vascepa for the reduction of cardiovascular risk in...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that it will be participating in Renmark...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Bill Wells, Executive Chair of the...
Quebec becomes the first province to reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular disease Private drug plan reimbursement for Vascepa is...
Q1 2022 revenue of $14.6 million, Adjusted EBITDA of $6.3 million and cash from operations of $5.8 million. Vascepa® prescriptions grew 12% sequentially and 111% year-over-year in Q1 2022 amid...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 Fiscal 2022 financial results on Thursday, May 5, 2022. The Company will hold a conference call...
Enters into Letter of Intent (LOI) that paves the way for product listing agreements for Vascepa with all of Canada's provinces and territories. Public market access is expected to be a...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
Q4 2021 revenue of $15.7 million, Adjusted EBITDA of $6.2 million and cash from operations of $4.0 million 2021 revenue of $60.0 million, Adjusted EBITDA of $26.3 million and cash from operations...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q4 & Fiscal 2021 financial results on Thursday, March 17, 2022. The Company will hold a conference...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that in connection with its previously...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, Chief Executive...
Q3 2021 revenue of $15.1 million and Adjusted EBITDA of $6.9 million, up 15% and 53%, respectively, from Q3 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 2021 financial results on Thursday, November 4, 2021. The Company will hold a conference call that...